New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (NABOGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03294395

Recruitment Status : Completed

First Posted : September 27, 2017

Last Update Posted : August 6, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Information provided by (Responsible Party):

Henry J.C. de Vries, Public Health Service of Amsterdam

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 5, 2020
Actual Study Completion Date :	June 5, 2020

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	July 27, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

de Vries HJC, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, de Korne-Elenbaas J, van Dam AP, Schim van der Loeff MF; NABOGO steering group. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022 May;22(5):706-717. doi: 10.1016/S1473-3099(21)00625-3. Epub 2022 Jan 19.

To Top